Small Molecules
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
42
NCT06737250
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 25, 2024
Completion: Dec 31, 2027
NCT07114367
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Phase: Phase 1
Start: Sep 1, 2025
Loading map...